On 10 July 2026 the Bundestag reshaped Germany’s reimbursed medical cannabis market — striking dried flower from statutory cover and gating extracts, dronabinol and nabilone behind a six-month trial of an approved finished medicine. On our figures that puts roughly €205 million — about 82% of a €248.8 million market — in play. This is the full read behind the headline: how Germany got here, what the vote does, and why the clinical case is more than an accounting one.
Table of Contents
Germany did not arrive here overnight. The six-month gate is the end point of a four-month legislative acceleration layered on top of a nine-year settlement. Since 2017, seriously ill patients have held a statutory right to have cannabis therapy paid for by their health fund. What changed on 10 July is not whether cannabis is reimbursed, but which forms the state will pay for, and in what order.
Read alongside our data, the move looks less like cost-cutting and more like a structural reset: the reform privileges the one category demand has been leaving, and restricts the categories patients and prescribers have migrated towards. What follows is the sequence, the numbers, the economics and the clinical arguments — the version that does not fit in a LinkedIn post.
How we got here
The gate is the product of a nine-year entitlement and a four-month scramble to narrow it.
- March 2017 — The “Cannabis als Medizin” law creates the §31(6) SGB V entitlement: seriously ill patients gain a right to reimbursed flower, extracts, dronabinol/nabilone or approved medicines where standard therapy has failed.
- April 2024 — The CanG partial legalisation removes cannabis from the Narcotics Act; the patient base scales from roughly 250,000 towards about 900,000 by mid-2025.
- 31 March 2026 — The Finanzkommission Gesundheit recommends ending flower reimbursement in favour of extracts, projecting about €130 million a year in savings.
- 16 April 2026 — The Health Ministry drafts the Contribution Stabilisation Act (BStabG), striking flower from §31(6).
- 9 June 2026 — Vertanical’s Exilby wins German authorisation for chronic low back pain — the first newly approved finished cannabis medicine since Canemes.
- 22 June 2026 — At the Bundestag hearing, patient and industry groups (BDCan, VCA, DHV) contest the flower cut.
- 5–7 July 2026 — A late amendment mandates a six-month finished-medicine trial for extracts, dronabinol and nabilone — almost the entire compounded market.
- 8 July 2026 — The Health Committee adopts the amendment unchanged, with no grandfathering for existing patients.
- 10 July 2026 — The Bundestag passes the BStabG.
The sequence is telling. In March the same commission argued for extracts against flower, on standardisation and exact dosing; four months later the reform gates extracts too. In one legislative season the goalposts moved from “standardised formats” to “approved products” — the licensed-pharmaceutical logic that Exilby’s authorisation had just made available.
What the Bundestag changed
Source: Cannamonitor GKV dataset (GKV-Gamsi). The 2020 and 2025 splits show the mix inverting; the column chart tracks the path year by year.
The reform removes dried cannabis flower from §31(6) SGB V and makes extracts, dronabinol and nabilone reimbursable only after a six-month trial of an approved finished medicine. On our GKV figures that exposes roughly €205 million — about 82% of a €248.8 million market in 2025: €124.7 million of flower struck outright, and around €80 million of extracts and isolates gated behind the trial.
The two circles show the mix inverting between 2020 and 2025: extracts leapt from 5% to 20% of reimbursed spend while isolates halved. The one category the reform leaves untouched — finished pharmaceuticals, at €44.1 million — is the smallest slice of all. The limits are expected to apply from 1 January 2027, subject to Bundesrat handling.
A restructuring, not a saving
The categories being cut or gated are the market’s growth engines; the category the law privileges is the one demand has been leaving. Flower is up 74% since 2020 and extracts have grown almost sixfold (5.7×), while finished pharmaceuticals like Epidyolex and Sativex, standing at €44.1 million — are the smallest segment and have declined since 2023 in favour of more affordable compounded therapies.
The cost case sits awkwardly against the prices. A peer-reviewed study in the International Journal of Drug Policy found median flower prices fell 31% in eleven months to November 2025. Yet the reimbursed channel still pays pharmacies €13–19 per gram under a Hilfstaxe schedule unchanged since 2020 — for product trading openly near €5 per gram. The cost problem is largely a pricing-rule problem.
The reform also presumes an available, reimbursed finished product. Exilby is authorised only for chronic low back pain with a radicular component — a slice of the 76.4% of patients treated for chronic pain — and is neither priced nor launched. With launch expected around September 2026 and the rule applying from January 2027, no patient could complete a six-month trial before it takes effect.
The clinical case for compounded preparations
The case for compounded preparations is clinical, not just economic. A pharmacy-compounded oil or dried-flower preparation can be matched to the patient in concentration, dosage form and route, where finished medicines come in fixed strengths. Inhaled flower acts within minutes for breakthrough pain or nausea, with only a couple of CE-certified medical devices being available for to inhale extracts instead of flower. In any case, determining which preparation suits a patient should rest with the treating physician, not statute.
Approved products are also licensed for very few indications — three medicines for spasticity in MS (Sativex), rare forms of epilepsy (Epidyolex) and Exilby for one slice of back pain. For the chronic-pain majority and everything off-label, the rule forces a finished-medicine trial that needs separate justification (VCA) — and with no grandfathering, stabilised patients must disrupt a working regimen first (BvCW).
The economics then cut against the reform: about €2–3 a day for dronabinol and €6–10 for a magistral extract, versus roughly €46 for a finished product. By mandating the dearest option first, the rule suspends the efficiency principle (§12 SGB V) the system is built on.
What to watch
The savings are contested even on the government’s own numbers, and the offsets it omits — substitution away from other medicines and sharp price deflation — cut the other way. Industry bodies note that the €205 million at stake is a rounding error against a funding gap projected at up to €40 billion by 2030, and warn of follow-on costs. Around 65,000 statutory patients could lose reimbursement.
Three things will decide how this lands: the Bundesrat, where industry is pressing for a shorter or deleted trial, exception clauses and grandfathering; Exilby securing pricing agreement; and the substitution patterns that emerge in 2026–27 reimbursement data. The wider backdrop is a European market splitting in two between self-paying, recreationally-inclined markets, and reimbursed, pharma-oriented schemes.